RaQualia Pharma Inc.
TTSE:4579632.00
JPY
-6.00
(-0.94%)
ISIN
JP3967150008
Return %
Stock
S&P 500
1Y
14.91
14.20
3Y
-3.95
81.12
5Y
-35.18
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Masaki Sudo
- Full Time Employees
- 85
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Meieki Southside Square Nagoya AI Japan 450-0003
- IPO Date
- Jul 20, 2011
- Website
- raqualia.com
- Similar Companies
- Business
- RaQualia Pharma Inc. is dedicated to the innovative discovery and development of therapeutic compounds across global markets. The company's human health portfolio features several promising assets, including tegoprazan, a potassium-competitive acid blocker for gastroesophageal reflux disease, which has achieved broad market approval in countries such as South Korea, China, and Malaysia, with ongoing development or review in numerous additional territories, while the company retains its Japanese rights for this asset. Another significant human program involves a novel sodium channel blocker licensed for chronic pain, and tamibarotene, which is in investigator-initiated Phase I/II trials for pancreatic cancer in Japan and has received Fast-Track designation from the U.S. FDA for higher-risk myelodysplastic syndrome. Additionally, the pipeline includes a ghrelin receptor agonist that has completed preclinical studies for constipation and cancer-related anorexia/cachexia syndrome, and a TRPM8 blocker for chronic pain. In the veterinary sector, the company provides several marketed products, such as grapiprant (marketed as GALLIPRANT®) for canine osteoarthritis, and capromorelin (marketed as ENTYCE™ and ELURA™) for appetite stimulation in dogs and managing weight loss in cats with chronic kidney disease, respectively, all distributed by licensees. Recent collaborations include an exclusive option agreement with Velovia Pharma for four compounds targeting gastrointestinal, metabolic, and fibrotic conditions in animals, and a partnership with Vetbiolix SAS for RQ-00000010, a 5-HT4 agonist for canine and feline gut motility disorders, which Vetbiolix has recently opted to license. RaQualia Pharma operates as a research and development-focused biotechnology firm, generating revenue through upfront payments, milestone achievements, and royalties from its out-licensed compounds to pharmaceutical partners. The company leverages its origins as a spin-off from Pfizer's central research laboratory in Japan, excelling in challenging areas like ion channel drug discovery and expanding into new modalities such as mRNA-targeted small molecule drugs through collaborations with entities like Veritas In Silico. The firm was established in 2008 and maintains its headquarters in Nagoya, Japan.